The humoral immune response generated by two commercial influenza vaccines was evaluated in a randomised, double-blind trial performed in the Public Department of Dolo Health District (Northeast Italy) during the winter season 1997-1998.
Ninety-eight subjects were immunised with a split virus vaccine and ninety-six with a MF59-adjuvanted subunit virus vaccine (SU/MF59).
The pre-and postvaccination (~30 days) antibody titres were determined by hemagglutination inhibition test (HI).
After immunisation protective titre rates (>=1 : 40) were near 100% against virus A strain and 82.5% against B strain.
Both vaccines caused significant rises in geometric mean antibody titres (GMTs) ; however, people who received SU/MF59 vaccine were found to develop a greater immune response compared to the group immunised with SVV.
According to logistic regression analysis the unprotective prevaccination immune status and the use of SU/MF59 were identified as independent factors significantly increasing the response to immunisation.
Mots-clés Pascal : Vaccination, Grippe, Virose, Infection, Anticorps, Sérologie, Réponse immune, Plasma sanguin, Epidémiologie, Evaluation, Efficacité, Adulte, Homme, Italie, Europe
Mots-clés Pascal anglais : Vaccination, Influenza, Viral disease, Infection, Antibody, Serology, Immune response, Blood plasma, Epidemiology, Evaluation, Efficiency, Adult, Human, Italy, Europe
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0465064
Code Inist : 002B05A02. Création : 22/03/2000.